Hillgene Completed the Pre-A+ Round Funding up to Tens of Millions of Dollars Again Constant Enhancing the Capability of CQDMO Services in the Industry of Cellular Therapy Product
Jiangsu Puxin Biopharmaceutical Co., Ltd. ("Puxin Bio" or "the Company") has continued to attract capital attention within two months after the completion of the Pre-A round of fin...
More+
Full text of the new “Drug Administration Law of the People's Republic of China”
City license. The transferee shall have the quality management, risk prevention and control, and liability compensation capabilities to ensure the safety, effectiveness, and quality controllability of...
More+
Understanding Cell Therapy Products and Their Applications
The realm of modern medicine is continually evolving, introducing cutting-edge treatments like cell therapy products that offer new hope for a wide range of medical conditions. As the demand for perso...
More+
What CDMO Means in Pharmaceutical Manufacturing
The pharmaceutical industry is a complex ecosystem that involves various players and processes aimed at delivering safe and effective treatments to patients worldwide. One of these key players is the ...
More+
Benefits and Risks of Stem Cell Products
The rapid advancement in biomedical research has propelled cell therapy products into the limelight as a novel solution for a variety of medical conditions. These innovative interventions have shown p...
More+
E1A & SV40LTA Residual DNA Detection Kit (Multiplex qPCR)
This kit is designed for the rapid and specific detection of residual E1A & SV40LTA DNA derived from host cell (e.g., HEK293 cell) in biological products.This kit adopts the fluorescent probe meth...
More+
Hillgene Reached a Strategic Cooperation with T-Maximum in Accelerating the innovation and Breakthrough of Universal Cells
Recently, Jiangsu Puxin Biopharmaceutical Co., Ltd. (hereinafter referred to as "Puxin Biopharmaceutical") and Maoxing Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as &quo...
More+
NMPA (formerly CFDA) Solicits Public Comments on “Good Manufacturing Practice (GMP) – Appendix for Cellular Therapy Drugs” (Draft for Comments)
Chapter 1 ScopeArticle 1 [Scope] The cell therapy products described in this appendix refer to living cell products of human origin, including products produced by cell lines, as well as immune cells,...
More+
Official Operation of Hillgene R&D Center, Boosting the Innovation of the Biopharmaceutical Industry in Wuzhong District
This morning (June 28), the ribbon-cutting ceremony for the official operation of Spectrum Biotechnology R&D Center was held. Gu Hongjian, member of the Party Working Committee and deputy director...
More+
The Comprehensive Affairs Department of NMPA Solicits Public Comments on “Inspection Procedures of Drug Product MAHs (Draft for Comments)”
1. PurposeThis procedure is formulated to implement the Drug Administration Law of the People's Republic of China and the Vaccine Administration Law of the People's Republic of China, fully im...
More+